[{"id":"e726abe0-9a61-4e1d-8970-9b7613e8839f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03522142","created_at":"2021-01-18T17:20:30.581Z","updated_at":"2024-07-02T16:34:37.560Z","phase":"Phase 1","brief_title":"A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies","source_id_and_acronym":"NCT03522142","lead_sponsor":"Incyte Corporation","biomarkers":" FLT3 • MSI • IDH1 • IDH2","pipe":" | ","alterations":" MSI-H/dMMR • FLT3-ITD mutation • FLT3 wild-type • IDH wild-type","tags":["FLT3 • MSI • IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • FLT3-ITD mutation • FLT3 wild-type • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • INCB81776"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 08/27/2018","start_date":" 08/27/2018","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-06"},{"id":"3102105e-b831-48d9-b839-01e75ece3f9a","acronym":"COVALENT-103","url":"https://clinicaltrials.gov/study/NCT05918692","created_at":"2023-06-26T14:09:14.079Z","updated_at":"2024-07-02T16:35:00.712Z","phase":"Phase 1","brief_title":"A Phase 1, Study of BMF-500 in Adults With Acute Leukemia","source_id_and_acronym":"NCT05918692 - COVALENT-103","lead_sponsor":"Biomea Fusion Inc.","biomarkers":" FLT3 • NPM1","pipe":" | ","alterations":" FLT3 mutation • NPM1 mutation • FLT3 wild-type","tags":["FLT3 • NPM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • NPM1 mutation • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BMF-500"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 07/26/2023","start_date":" 07/26/2023","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2024-05-27"},{"id":"4709cf4b-f7f6-4c8f-8b77-5a8ac8771021","acronym":"","url":"https://clinicaltrials.gov/study/NCT03674411","created_at":"2021-01-18T18:01:23.529Z","updated_at":"2024-07-02T16:35:10.273Z","phase":"Phase 2","brief_title":"Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy","source_id_and_acronym":"NCT03674411","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" FLT3 • NPM1 • KMT2A • HLA-DRB1 • CEBPA","pipe":" | ","alterations":" FLT3-ITD mutation • NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation • FLT3 wild-type","tags":["FLT3 • NPM1 • KMT2A • HLA-DRB1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • busulfan • cyclophosphamide intravenous • spanlecortemlocel (MGTA-456)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 01/02/2019","start_date":" 01/02/2019","primary_txt":" Primary completion: 06/23/2020","primary_completion_date":" 06/23/2020","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-04-10"},{"id":"d2fff3d6-ffea-4d7d-80f3-4801459b6711","acronym":"","url":"https://clinicaltrials.gov/study/NCT04659616","created_at":"2021-01-19T20:42:17.932Z","updated_at":"2024-07-02T16:35:10.819Z","phase":"Phase 1","brief_title":"Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT04659616","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" TP53 • FLT3 • ABL1 • BCR • EZH2 • RUNX1 • SF3B1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • MLLT3 • CDKN1A • DEK • ZRSR2","pipe":" | ","alterations":" TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • BCOR mutation • Chr del(5q) • STAG2 mutation • FLT3 wild-type • Chr t(9;11) • ZRSR2 mutation","tags":["TP53 • FLT3 • ABL1 • BCR • EZH2 • RUNX1 • SF3B1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • MLLT3 • CDKN1A • DEK • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • BCOR mutation • Chr del(5q) • STAG2 mutation • FLT3 wild-type • Chr t(9;11) • ZRSR2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Pemazyre (pemigatinib) • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-04-09"},{"id":"b62639b3-3bfc-4f4f-81ac-2892933d901a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05115630","created_at":"2021-11-10T14:13:02.708Z","updated_at":"2024-07-02T16:35:19.132Z","phase":"Phase 1/2","brief_title":"Off-the-shelf NK Cells + SCT for Myeloid Malignancies","source_id_and_acronym":"NCT05115630","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • FLT3 • ABL1 • BCR • NPM1 • RUNX1 • ASXL1 • KMT2A • MECOM • NUP214 • GATA2 • DEK","pipe":" | ","alterations":" TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • MLL rearrangement • Chr del(5q) • FLT3 wild-type","tags":["TP53 • FLT3 • ABL1 • BCR • NPM1 • RUNX1 • ASXL1 • KMT2A • MECOM • NUP214 • GATA2 • DEK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • MLL rearrangement • Chr del(5q) • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • mesna • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 04/08/2022","start_date":" 04/08/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-02-16"},{"id":"0f841029-f2ce-4cb1-849c-75709569b46f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03613532","created_at":"2021-03-05T16:52:31.672Z","updated_at":"2024-07-02T16:35:22.047Z","phase":"Phase 1","brief_title":"Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN","source_id_and_acronym":"NCT03613532","lead_sponsor":"Jacqueline Garcia, MD","biomarkers":" KRAS • TP53 • FLT3 • ABL1 • NRAS • BCR • BCL2 • NPM1 • NF1 • RUNX1 • SF3B1 • ASXL1 • KMT2A • PTPN11 • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • DEK • RIT1 • ZRSR2","pipe":" | ","alterations":" TP53 mutation • KRAS mutation • NRAS mutation • RUNX1 mutation • RAS mutation • ASXL1 mutation • CBL mutation • MLL rearrangement • U2AF1 mutation • Chr del(5q) • FLT3 wild-type","tags":["KRAS • TP53 • FLT3 • ABL1 • NRAS • BCR • BCL2 • NPM1 • NF1 • RUNX1 • SF3B1 • ASXL1 • KMT2A • PTPN11 • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • DEK • RIT1 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • KRAS mutation • NRAS mutation • RUNX1 mutation • RAS mutation • ASXL1 mutation • CBL mutation • MLL rearrangement • U2AF1 mutation • Chr del(5q) • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Inqovi (decitabine/cedazuridine) • fludarabine IV • busulfan"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 10/24/2018","start_date":" 10/24/2018","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-01-26"},{"id":"5d7622ad-719f-47cd-90a0-999fd39d85cf","acronym":"FLYSYN-101","url":"https://clinicaltrials.gov/study/NCT02789254","created_at":"2021-01-18T13:41:02.192Z","updated_at":"2024-07-02T16:35:24.982Z","phase":"Phase 1/2","brief_title":"FLYSYN in MRD Positive AML","source_id_and_acronym":"NCT02789254 - FLYSYN-101","lead_sponsor":"Synimmune GmbH","biomarkers":" FLT3 • NPM1","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 wild-type • FLT3 expression","tags":["FLT3 • NPM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 wild-type • FLT3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VX-A901"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 02/07/2017","start_date":" 02/07/2017","primary_txt":" Primary completion: 09/27/2021","primary_completion_date":" 09/27/2021","study_txt":" Completion: 09/27/2021","study_completion_date":" 09/27/2021","last_update_posted":"2023-12-28"},{"id":"df5b5086-1697-4c00-8ecc-c22d551b5706","acronym":"","url":"https://clinicaltrials.gov/study/NCT02339740","created_at":"2021-01-18T11:07:04.205Z","updated_at":"2024-07-02T16:35:28.404Z","phase":"Phase 3","brief_title":"Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT02339740","lead_sponsor":"Children's Oncology Group","biomarkers":" FLT3 • RARA • PML","pipe":" | ","alterations":" FLT3 mutation • FLT3 wild-type","tags":["FLT3 • RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • mitoxantrone • Vesanoid (tretinoin) • arsenic trioxide • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 158","initiation":"Initiation: 07/21/2015","start_date":" 07/21/2015","primary_txt":" Primary completion: 10/31/2020","primary_completion_date":" 10/31/2020","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2023-11-22"},{"id":"9ec918d6-6c66-45cd-b449-933f7666cefc","acronym":"Q-SOC","url":"https://clinicaltrials.gov/study/NCT04676243","created_at":"2021-07-12T07:53:02.092Z","updated_at":"2024-07-02T16:36:09.925Z","phase":"Phase 3","brief_title":"Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML","source_id_and_acronym":"NCT04676243 - Q-SOC","lead_sponsor":"University Hospital Heidelberg","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 wild-type","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • midostaurin • Vanflyta (quizartinib) • daunorubicin • idarubicin hydrochloride"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/01/2022","start_date":" 05/01/2022","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2022-05-25"},{"id":"b185f5af-b20b-432d-b8f0-d2a61b2a09b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03412292","created_at":"2021-01-18T16:50:05.305Z","updated_at":"2024-07-02T16:36:18.334Z","phase":"Phase 1","brief_title":"MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)","source_id_and_acronym":"NCT03412292","lead_sponsor":"Maxinovel Pty., Ltd.","biomarkers":" FLT3 • FGFR","pipe":" | ","alterations":" FLT3 wild-type","tags":["FLT3 • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Max-40279"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/01/2018","start_date":" 08/01/2018","primary_txt":" Primary completion: 11/01/2022","primary_completion_date":" 11/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2022-01-19"},{"id":"3595892a-b438-47a6-9905-bb90d4dc044d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02078609","created_at":"2021-01-18T09:34:53.711Z","updated_at":"2024-07-02T16:36:37.178Z","phase":"Phase 1","brief_title":"A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)","source_id_and_acronym":"NCT02078609","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FLT3 • EIF4EBP1","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 mutation • FLT3 wild-type","tags":["FLT3 • EIF4EBP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 mutation • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e midostaurin • PIM447"],"overall_status":"Completed","enrollment":" Enrollment 70","initiation":"Initiation: 03/20/2014","start_date":" 03/20/2014","primary_txt":" Primary completion: 04/18/2019","primary_completion_date":" 04/18/2019","study_txt":" Completion: 04/18/2019","study_completion_date":" 04/18/2019","last_update_posted":"2020-12-17"},{"id":"2ef611e5-e4d2-495b-9d85-9c12e33be63b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02428543","created_at":"2021-01-18T11:37:05.675Z","updated_at":"2024-07-02T16:36:42.191Z","phase":"Phase 1/2","brief_title":"Ponatinib for FLT3-ITD Acute Myelogenous Leukemia","source_id_and_acronym":"NCT02428543","lead_sponsor":"Versailles Hospital","biomarkers":" FLT3 • NPM1 • WT1","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 mutation • NPM1 mutation • FLT3 wild-type • NPM1 expression","tags":["FLT3 • NPM1 • WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 mutation • NPM1 mutation • FLT3 wild-type • NPM1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Iclusig (ponatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 07/01/2013","start_date":" 07/01/2013","primary_txt":" Primary completion: 11/01/2020","primary_completion_date":" 11/01/2020","study_txt":" Completion: 11/01/2023","study_completion_date":" 11/01/2023","last_update_posted":"2020-08-10"},{"id":"c40b3055-b76a-4281-b438-b731c940b17c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00045578","created_at":"2021-07-12T07:52:33.666Z","updated_at":"2024-07-02T16:37:18.942Z","phase":"Phase 1/2","brief_title":"PKC412 With or Without Itraconazole in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT00045578","lead_sponsor":"Memorial Sloan-Kettering Cancer Center","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation • FLT3 wild-type","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e midostaurin • itraconazole"],"overall_status":"Completed","enrollment":"","initiation":"Initiation: 03/01/2002","start_date":" 03/01/2002","primary_txt":" Primary completion: 07/01/2004","primary_completion_date":" 07/01/2004","study_txt":"","study_completion_date":"","last_update_posted":"2017-08-11"},{"id":"c7fe2208-b4d9-4900-9f11-708ea5073093","acronym":"","url":"https://clinicaltrials.gov/study/NCT00977782","created_at":"2021-07-12T07:52:38.151Z","updated_at":"2024-07-02T16:37:18.946Z","phase":"Phase 1/2","brief_title":"Open-label Multicenter Study of PKC412 in Pts With AML and MDS With Either Wild-type or Mutated FLT3","source_id_and_acronym":"NCT00977782","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation • FLT3 wild-type","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e midostaurin"],"overall_status":"Completed","enrollment":" Enrollment 95","initiation":"Initiation: 03/01/2003","start_date":" 03/01/2003","primary_txt":" Primary completion: 05/01/2008","primary_completion_date":" 05/01/2008","study_txt":" Completion: 10/01/2008","study_completion_date":" 10/01/2008","last_update_posted":"2017-08-11"}]